BOULDER, Colo., Nov. 8, 2017 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Operating Officer, Andy Robbins, will present at the 2017 Stifel Healthcare Conference. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.
Event: | Stifel Healthcare Conference |
Presenter: | Andy Robbins, Chief Operating Officer |
Date: | Wednesday, November 15, 2017 |
Time: | 11:00 a.m. Eastern Time |
Webcast: |
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Nine registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics).
CONTACT: | Tricia Haugeto |
Array BioPharma Inc. | |
303-386-1193 | |
View original content with multimedia:http://www.prnewswire.com/news-releases/array-biopharma-to-present-at-the-2017-stifel-healthcare-conference-300551492.html
SOURCE Array BioPharma
